Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023;329:574–87. https://doi.org/10.1001/jama.2023.0023.

Article  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51. https://doi.org/10.1093/neuonc/noab106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stupp R, Mason WP, Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. https://doi.org/10.1056/NEJMoa043330.

Article  CAS  PubMed  Google Scholar 

Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306–16. https://doi.org/10.1001/jama.2017.18718.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507. https://doi.org/10.1056/NEJMra050276.

Article  CAS  PubMed  Google Scholar 

di Chiro G, Brooks RA, Patronas NJ, Bairamian D, Kornblith PL, Smith BH, et al. Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol. 1984;15:138–46. https://doi.org/10.1002/ana.410150727.

Article  Google Scholar 

Arora G, Sharma P, Sharma A, Mishra AK, Hazari PP, Biswas A, et al. 99mTc-methionine hybrid SPECT/CT for detection of recurrent glioma: comparison with 18F-FDG PET/CT and contrast-enhanced MRI. Clin Nucl Med. 2018;43:e132–8. https://doi.org/10.1097/rlu.0000000000002036.

Article  PubMed  Google Scholar 

Unterrainer M, Schweisthal F, Suchorska B, Wenter V, Schmid-Tannwald C, Fendler WP, et al. Serial 18F-FET PET imaging of primarily 18F-FET-negative glioma: does it make sense? J Nucl Med. 2016;57:1177–82. https://doi.org/10.2967/jnumed.115.171033.

Article  CAS  PubMed  Google Scholar 

Maurer GD, Brucker DP, Stoffels G, Filipski K, Filss CP, Mottaghy FM, et al. (18)F-FET PET imaging in differentiating glioma progression from treatment-related changes: a single-center experience. J Nucl Med. 2020;61:505–11. https://doi.org/10.2967/jnumed.119.234757.

Article  PubMed  Google Scholar 

Langen K-J, Galldiks N. Update on amino acid PET of brain tumours. Curr Opin Neurol. 2018;31:354–61. https://doi.org/10.1097/wco.0000000000000574.

Article  CAS  PubMed  Google Scholar 

Cicone F, Filss CP, Minniti G, Rossi-Espagnet C, Papa A, Scaringi C, et al. Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. Eur J Nucl Med Mol Imaging. 2015;42:905–15. https://doi.org/10.1007/s00259-015-3018-5.

Article  CAS  PubMed  Google Scholar 

García Vicente AM, Pérez-Beteta J, Bosque JJ, Soriano Castrejón ÁM, Pérez-García VM. Multiple and diffuse gliomas by 18F-fluorocholine PET/CT: two sides of the same coin. Clin Nucl Med. 2022;47:e457–65. https://doi.org/10.1097/rlu.0000000000004145.

Article  PubMed  Google Scholar 

Brahm CG, den Hollander MW, Enting RH, de Groot JC, Solouki AM, den Dunnen WFA, et al. Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. Eur J Nucl Med Mol Imaging. 2018;45:2404–12. https://doi.org/10.1007/s00259-018-4090-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 10): a report of the RANO group. Lancet Oncol. 2024;25:e29–41. https://doi.org/10.1016/S1470-2045(23)00525-9.

Article  PubMed  Google Scholar 

Sharif TR, Luo W, Sharif M. Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway. Mol Cell Endocrinol. 1997;130:119–30. https://doi.org/10.1016/s0303-7207(97)00080-4.

Article  CAS  PubMed  Google Scholar 

Flores DG, Meurer L, Uberti AF, Macedo BR, Lenz G, Brunetto AL, et al. Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res Bull. 2010;82:95–8. https://doi.org/10.1016/j.brainresbull.2010.02.014.

Article  CAS  PubMed  Google Scholar 

Moody TW, Mahmoud S, Staley J, Naldini L, Cirillo D, South V, et al. Human glioblastoma cell lines have neuropeptide receptors for bombesin/gastrin-releasing peptide. J Mol Neurosci. 1989;1:235–42.

CAS  PubMed  Google Scholar 

Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res. 1994;54:5895–901.

CAS  PubMed  Google Scholar 

de Oliveira MS, Cechim G, Braganhol E, Santos DG, Meurer L, de Castro CG, et al. Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J Neurooncol. 2009;93:191–201. https://doi.org/10.1007/s11060-008-9775-2.

Article  CAS  PubMed  Google Scholar 

Breeman WAP, Verbruggen AM. The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine? Eur J Nucl Med Mol Imaging. 2007;34:978–81. https://doi.org/10.1007/s00259-007-0387-4.

Article  PubMed  PubMed Central  Google Scholar 

Zhang J, Li D, Lang L, Zhu Z, Wang L, Wu P, et al. 68Ga-NOTA-Aca-BBN(7–14) PET/CT in healthy volunteers and glioma patients. J Nucl Med. 2016;57:9–14. https://doi.org/10.2967/jnumed.115.165316.

Article  CAS  PubMed  Google Scholar 

Bodei L, Ferrari M, Nunn A, Llull J, Cremonesi M, Martano L, et al. Lu-177-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. In: European journal of nuclear medicine and molecular imaging. SPRINGER 233 SPRING STREET, NEW YORK, NY 10013 USA; 2007. p. S221-S.

Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318–26. https://doi.org/10.2967/jnumed.107.045054.

Article  CAS  PubMed  Google Scholar 

Varasteh Z, Velikyan I, Lindeberg G, Sörensen J, Larhed M, Sandström M, et al. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging. Bioconjug Chem. 2013;24:1144–53. https://doi.org/10.1021/bc300659k.

Article  CAS  PubMed  Google Scholar 

Mansi R, Wang X, Forrer F, Kneifel S, Tamma M-L, Waser B, et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res. 2009;15:5240–9. https://doi.org/10.1158/1078-0432.CCR-08-3145.

Article  CAS  PubMed  Google Scholar 

Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, et al. PET using a GRPR antagonist (68)Ga-RM26 in healthy volunteers and prostate cancer patients. J Nucl Med. 2018;59:922–8. https://doi.org/10.2967/jnumed.117.198929.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zang J, Mao F, Wang H, Zhang J, Liu Q, Peng L, et al. 68Ga-NOTA-RM26 PET/CT in the evaluation of breast cancer: a pilot prospective study. Clin Nucl Med. 2018;43:663–9. https://doi.org/10.1097/rlu.0000000000002209.

Article  PubMed  PubMed Central  Google Scholar 

Loose D, Signore A, Staelens L, Bulcke KV, Vermeersch H, Dierckx RA, et al. 123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma. Eur J Nucl Med Mol Imaging. 2008;35:281–6. https://doi.org/10.1007/s00259-007-0609-9.

Article  CAS  PubMed  Google Scholar 

Hart E, Odé Z, Derieppe MPP, Groenink L, Heymans MW, Otten R, et al. Blood–brain barrier permeability following conventional photon radiotherapy—a systematic review and